American football hero Montana backs Novartis' Lotrel
US football hero Joe Montana has signed a two-year deal with Novartis to back a hypertension awareness campaign that includes promoting the firm's antihypertensive drug Lotrel (amlodipine and benazepril hydrochloride). The campaign started late-August and the terms of the contract are not disclosed, according to a report by Forbes magazine.
Joe Montana, who was famed for never showing stress as the opposing linemen closed in, becomes the latest in a growing list of celebrities signing deals with drugmakers, says Forbes, noting that, in late-July, one-time Chicago Bears coach Mike Ditka signed up to help promote Bayer and GlaxoSmithKline's erectile dysfunction drug Levitra (vardenafil).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze